TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05484726

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: perioral sensory motor stimulation
Description: Step 1 - 6 over 5 minutes~1 With the help of the index finger, on the external surface of the cheek, make a circle starting from the angle of the mouth towards the ear then back 7x each cheek~2 While holding both sides of the cheek with help of the thumb and index finger repeat step 1 7x each cheek~3 Move index finger from one corner to opposite one over both lips separately 7x each lip~4 Gentle massage and compress the gums from center to back of mouth 7x each half of the gum~5 Move the finger from front to back on the hard palate while applying gentle pressure 7x~6 Displace the center of the tongue with gentle pressure 7x~7 Offer pacifier at the end 2 minutes~Note: 7x means 7 times

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: perioral sensory motor stimulation
Description: Step 1 - 6 over 5 minutes~1 With the help of the index finger, on the external surface of the cheek, make a circle starting from the angle of the mouth towards the ear then back 7x each cheek~2 While holding both sides of the cheek with help of the thumb and index finger repeat step 1 7x each cheek~3 Move index finger from one corner to opposite one over both lips separately 7x each lip~4 Gentle massage and compress the gums from center to back of mouth 7x each half of the gum~5 Move the finger from front to back on the hard palate while applying gentle pressure 7x~6 Displace the center of the tongue with gentle pressure 7x~7 Offer pacifier at the end 2 minutes~Note: 7x means 7 times
Study: NCT05866510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Utidelone and anlotinib
Description: Pretreatment: diphenhydramine 40 mg by intramuscular injection or oral administration, and dexamethasone10 mg and cimetidine 300 mg by intravenous injection 30 minutes prior to Utidelone iv drip at the first day of each cycle.~Utidelone will be given at 30 mg/m2/d administered intravenously on days 1-5 and Anlotinib 8mg/d took orally on days 1-14 every 21 days.
Study: NCT05636579

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EO2002
Description: Intracameral injection of magnetic human corneal endothelial cells (EO2002)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EO2002
Description: Intracameral injection of magnetic human corneal endothelial cells (EO2002)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ripasudil
Description: Daily use of Ripasudil drops
Study: NCT05856799

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Leadless Micra AV Transcatheter Pacing System
Description: Patients are implanted with a leadless Micra AV TPS

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transvenous Azure XT DR dual chamber pacemaker
Description: Patients are implanted with a transvenous Azure XT DR pacemaker
Study: NCT06330272

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Application of dental mousse based on CPP-ACPF
Description: Treatment will begin with pumice prophylaxis of incisors with IMH lesions. After this step, the teeth will be dried before applying dental foam based on CPP-ACPF (Tooth Mousse PlusTM, GC Corporation, Tokyo, Japan).~The application of Tooth Mousse PlusTM to the MIH lesion will be carried out under relative isolation and with the aid of a microbrush. The cream will remain on the surface for 1 minute, which will be timed. The application will be carried out once a week, for four consecutive weeks.
Study: NCT04906889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Hydrochloride
Description: dexmedetomidine iv bolus for 10 minutes followed by the infusion of 0.1-1 ug/kg/h during general anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil Hydrochloride
Description: remifentanil iv infusion of 0.5-5 ng/ml (effect site concentration using TCI) during general anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride
Description: lidocaine iv bolus followed by the infusion of 1.5mg/kg/h during general anesthesia
Study: NCT05299203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapropterin dihydrochloride tablets
Description: dose escalation phase (BH4) aqueous solution is sprayed onto the skin of all radiotherapy areas, 3 times a day until two weeks after the end of radiotherapy.
Study: NCT04569058

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Photobiomodulation
Description: Transcranial Photobiomodulation--a noninvasive intervention in which near-infrared light (850 nanometer) is applied to forebrain.
Study: NCT06175715

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: carotid endarterectomy
Description: carotid endarterectomy under local or general anethesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: carotid endarterectomy
Description: carotid endarterectomy under local or general anethesia
Study: NCT06519760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-C1
Description: 68Ga-C1 is injected intravenously with a dose of 0.05-0.10 mCi/kg
Study: NCT06216171

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adaptive Radiotherapy
Description: Adaptive Radiotherapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: image guided radiotherapy without online adaptation
Description: image guided radiotherapy without online adaptation
Study: NCT06069856

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron Folic Acid Tablets with 60 mg of iron
Description: IFA with 60 mg iron is an intervention group. IFA with 60 mg of iron will be taken orally once daily from the time of randomization

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron Folic Acid Tablets with 60 mg of iron
Description: IFA with 60 mg iron is an intervention group. IFA with 60 mg of iron will be taken orally once daily from the time of randomization

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multiple Micronutrient Supplements with 60 mg of elemental iron
Description: MMS with 60 mg iron is an intervention group. MMS with 60 mg of iron plus standard UNIMMAP formulation for other 14 micronutrients will be taken orally once daily from the time of randomization.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multiple Micronutrient Supplements with 60 mg of elemental iron
Description: MMS with 60 mg iron is an intervention group. MMS with 60 mg of iron plus standard UNIMMAP formulation for other 14 micronutrients will be taken orally once daily from the time of randomization.
Study: NCT05265065

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tozinameran - Standard Dose
Description: Tozinameran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cellfree in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).~Dose - 30 µg in 0.3 ml. Liquid for injection. Single dose.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tozinameran - Standard Dose
Description: Tozinameran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cellfree in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).~Dose - 30 µg in 0.3 ml. Liquid for injection. Single dose.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tozinameran - Standard Dose
Description: Tozinameran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cellfree in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).~Dose - 30 µg in 0.3 ml. Liquid for injection. Single dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tozinameran - Fractional Dose
Description: Tozinameran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cellfree in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).~Dose - 15 µg in 0.15 ml. Liquid for injection. Single dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tozinameran - Fractional Dose
Description: Tozinameran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cellfree in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).~Dose - 15 µg in 0.15 ml. Liquid for injection. Single dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tozinameran - Fractional Dose
Description: Tozinameran is a single-stranded, 5'-capped messenger RNA (mRNA) produced using a cellfree in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).~Dose - 15 µg in 0.15 ml. Liquid for injection. Single dose.
Study: NCT05312411

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCRI-E2CAR_EGFRtv1
Description: Autologous CD4+ and CD8+ T cells that have been genetically modified to express antiFL(FITC-E2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UB_TT170
Description: Bispecific small molecule adapter formulated with phosphate buffered saline
Study: NCT06555263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luveltamab tazevibulin
Description: intravenous antibody-drug conjugate targeting FOLR1.
Study: NCT05744401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL002
Description: Administered via intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL002
Description: Administered via intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL002
Description: Administered via intravenous (IV) infusion
Study: NCT05775848

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BBP-418 (ribitol)
Description: The BBP-418 drug product is provided as Granules for Oral solution consisting of BBP-418 drug substance and silicon dioxide in a multilaminate sachet with a foil barrier. Silicon dioxide is generally regarded as safe and listed in the FDA IIAD. Silicon dioxide is a compendial excipient and is commonly used in pharmaceutical dosage forms. The BBP-418 Granules for Oral Solution are provided in sachets.The BBP-418 Granules for Oral Solution are reconstituted in water for oral administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BBP-418 (ribitol)
Description: The BBP-418 drug product is provided as Granules for Oral solution consisting of BBP-418 drug substance and silicon dioxide in a multilaminate sachet with a foil barrier. Silicon dioxide is generally regarded as safe and listed in the FDA IIAD. Silicon dioxide is a compendial excipient and is commonly used in pharmaceutical dosage forms. The BBP-418 Granules for Oral Solution are provided in sachets.The BBP-418 Granules for Oral Solution are reconstituted in water for oral administration.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: A placebo matched for similar taste and appearance was compounded at the clinical pharmacy with sucralose as a 0.35 mg/mL oral solution in purified water (USP) in a glass container. Sucralose is similar in taste to the compounded drug product.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A placebo matched for similar taste and appearance was compounded at the clinical pharmacy with sucralose as a 0.35 mg/mL oral solution in purified water (USP) in a glass container. Sucralose is similar in taste to the compounded drug product.
Study: NCT05735626

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Piperine 150μM + tDCS 2mA
Description: 2 days treatment with either sham + placebo or piperine 150μM + tDCS 2mA (cross-over randomized study).

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Piperine 1mM + tDCS 2mA
Description: 2 days treatment with either sham + placebo or piperine 1mM + tDCS 2mA (cross-over randomized study).

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Capsaicin 10μM + tDCS 2mA
Description: 2 days treatment with either sham + placebo or capsaicin 10μM + tDCS 2mA (cross-over randomized study).
Study: NCT05535660

Intervention type: DIAGNOSTIC_TEST
Intervention: Lipid panel
Description: fasting blood draw to examine concentrations of lipids in maternal blood during pregnancy
Study: NCT06125678

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Small intestinal contrast enhanced ultrasound followed by Computed tomography/Magnetic resonance enterography
Description: First small intestinal contrast enhanced ultrasound shall be done followed by CT enterography or MR enterography
Study: NCT05374915

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: REM-001 photodynamic therapy
Description: Infusion of REM-001 (iv) followed by light treatment to treatment field 24 hrs after infusion of REM-001
Study: NCT05108844

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Videocapsule endoscopy
Description: Endoscopic drop of videocapsule in duodenum after initial negative gastroscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Videocapsule endoscopy
Description: Endoscopic drop of videocapsule in duodenum after initial negative gastroscopy
Study: NCT04576715

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TEaM Intervention
Description: Multi-setting mTBI (mild traumatic brain injury) Evaluation and Management Intervention incorporates provider education and information technology support systems, based on the best available evidence and tailored to a specific environment (acute care setting vs primary care clinic). Facilitates linkages between providers (ED/UC to primary care) and systems (healthcare to school).~* Provider Training Modules: Training includes decision-making support alerted by positive triage screening and concussion-specific eMR template~* Management based on current best practices (however, may have additional education from the provider training)~* Return to school letters~* Primary Care Follow Up

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Continue with CHOA current best practices for mTBI:~* No TEaM Provider training (but will be offered to all providers at end of study)~* Will not be trained on utilization and implementation of the concussion screening alert and eMR template
Study: NCT04979845

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: Patients will receive telerehabilitation sessions for 12 weeks including aerobic and strengthening exercises

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Video exercise
Description: Patients will receive video instructions for home based exercises
Study: NCT04986124

Intervention type: OTHER
Intervention: treatment as usual
Description: No inervention. Treatment regime remains unchanged.
Study: NCT05547906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASCA101
Description: IV infusion Twice a Week, 8 times per each Cycle
Study: NCT05038891

Intervention type: DIAGNOSTIC_TEST
Intervention: Digital Cervical Exam
Description: Standard Digital Cervical Exam by an experienced OB provider

Intervention type: DIAGNOSTIC_TEST
Intervention: Digital Cervical Exam
Description: Standard Digital Cervical Exam by an experienced OB provider

Intervention type: DIAGNOSTIC_TEST
Intervention: Transperineal Ultrasound
Description: Self-administered transperineal ultrasound after instruction by a health care professional

Intervention type: DIAGNOSTIC_TEST
Intervention: Transperineal Ultrasound
Description: Self-administered transperineal ultrasound after instruction by a health care professional

Intervention type: DIAGNOSTIC_TEST
Intervention: Transvaginal Ultrasound
Description: Self-administered transvaginal ultrasound after instruction by a health care professional

Intervention type: DIAGNOSTIC_TEST
Intervention: Transvaginal Ultrasound
Description: Self-administered transvaginal ultrasound after instruction by a health care professional
Study: NCT05979506

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cutaneous wraps
Description: The topical treatment that will be used in this study are:~* For the body, an emollient cream with a high lipid content: Cold cream~* For the scalp and feet, an emollient preparation with keratolytic action: 10% or 30% urea, depending on the scalp and feet damage~Each of the 3 treatments (body, scalp and feet) will be carried out as follows:~* Application of different topicals all over the body and face, after taking a lukewarm therapeutic bath of 20 minutes~* Occlusion by wrapping the patient in a plastic film, then covering with a blanket~* After 1 hour, the unabsorbed excess cream is removed with a towel
Study: NCT05285800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5% Hyperbaric Bupivacaine
Description: In both groups 0.5% Hyperbaric Bupivacaine is given intrathecally and then saddle group is advised to stay in sitting position for next 5minutes so that drug can block only lower segments of nerves, Lumber 5th to Sacral dermatomes level. The spinal group is advised to take supine position immediately so that drug distribution be uniform uptill T10 level of spinal dermatome. Then outcomes regarding haemodynamic status and vasopressor usage are recorded

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5% Hyperbaric Bupivacaine
Description: In both groups 0.5% Hyperbaric Bupivacaine is given intrathecally and then saddle group is advised to stay in sitting position for next 5minutes so that drug can block only lower segments of nerves, Lumber 5th to Sacral dermatomes level. The spinal group is advised to take supine position immediately so that drug distribution be uniform uptill T10 level of spinal dermatome. Then outcomes regarding haemodynamic status and vasopressor usage are recorded
Study: NCT04871971

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 10 g NUTRALYS®S85 Plus pea protein
Description: To determine the glycaemic response and insulinaemic response to 50g Glucose + 10 g NUTRALYS®S85 Plus pea protein.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 20 g NUTRALYS®S85 Plus pea protein
Description: To determine the glycaemic response and insulinaemic response to 50g Glucose + 20 g NUTRALYS®S85 Plus pea protein.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 10 g Whey protein concentrate
Description: To determine the glycaemic response and insulinaemic response to 50g Glucose + 10 g Whey protein concentrate.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 20 g Whey protein concentrate
Description: To determine the glycaemic response and insulinaemic response to 50g Glucose + 20 g Whey protein concentrate.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: 50 g Glucose
Description: To determine the glycaemic response and insulinaemic response to 50g Glucose
Study: NCT05901714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afimetoran
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afimetoran
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenytoin
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Specified dose on specified days
Study: NCT06034834

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Near-infrared fluorescence imaging of perfusion
Description: Patients will undergo an intra-operative perfusion assessment using ICG NIR fluorescence imaging after clinical judgment and debridement of the traumatic injury. For patients undergoing additional debridement procedures, perfusion assessment with ICG will be repeated during every procedure.
Study: NCT05075096

Intervention type: OTHER
Intervention: No intervention.
Description: No intervention observational study.

Intervention type: OTHER
Intervention: No intervention.
Description: No intervention observational study.

Intervention type: OTHER
Intervention: No intervention.
Description: No intervention observational study.
Study: NCT06419634

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986497
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986497
Description: Specified dose on specified days
Study: NCT06195384

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neoantigen mRNA Vaccine
Description: Deliver neoantigen mRNA vaccine into patients for anti-ancer therapy.
Study: NCT05438680

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: The bovine colostrum ( trade name : baby steps sachets, 300mg )
Description: The bovine colostrum sachets will be used in a dose of 3.5ml/kg/ day , starting from the first 3 days after birth, for 14 days.~Enteral route, either through nasogastric tube or orally.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: distilled water with no bovine colostrum
Study: NCT05623995

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCSK9 inhibitor
Description: Evolocumab per every two weeks, starting at day 1 and up to week 48, added to guideline recommended statin therapy..

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Statin
Description: Guideline recommended statin therapy.
Study: NCT05837780

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nasoalveolar molding device
Description: comparison between using conventionally and digitally constructed nasoalveolar molding devices

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nasoalveolar molding device
Description: comparison between using conventionally and digitally constructed nasoalveolar molding devices